Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | IGM-7354 |
Synonyms | |
Therapy Description |
IGM-7354 is an anti-PD-L1 antibody fused to the cytokine IL-15, which potentially leads to enhanced proliferation of immune cells, antibody-dependent cellular cytotoxicity (ADCC) against PD-L1-positive tumor cells, and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3438). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IGM-7354 | IGM 7354|IGM7354 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | IGM-7354 is an anti-PD-L1 antibody fused to the cytokine IL-15, which potentially leads to enhanced proliferation of immune cells, antibody-dependent cellular cytotoxicity (ADCC) against PD-L1-positive tumor cells, and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3438). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05702424 | Phase I | IGM-7354 | Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | Active, not recruiting | USA | 0 |